Barrett Ablation denied as experimental or investigational by Humana?

Humana's specific coverage criteria for barrett ablation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Barrett's Esophagus Ablation as Experimental — and Why You Can Appeal

A denial of Barrett's esophagus ablation as "experimental" or "investigational" by Humana means the plan has determined, under its medical policy, that the evidence base for the requested ablative technique does not yet meet its standard for coverage as proven therapy. This denial reason is increasingly anomalous for established ablative techniques such as radiofrequency ablation, which have been reviewed and recognized by major gastroenterology professional societies as standard-of-care interventions for dysplastic Barrett's esophagus. However, experimental denials can still appear — particularly for newer or emerging ablation modalities — and they are often successfully challenged when the record shows that the specific technique requested has achieved broad clinical acceptance.

## Your Federal Appeal Rights

ACA §2719 requires that ACA-regulated plans provide a full internal appeal and independent external review. ERISA §503 governs employer plans. You have approximately four months from denial to request external review. Expedited review is available if your clinical situation makes standard timelines unsafe.

## The Appeal Process

1. Obtain the full denial letter. Humana must cite the specific policy language classifying this procedure as experimental and explain what evidence threshold was not met. 2. File a Level 1 internal appeal, including your physician's medical-necessity letter and peer-reviewed support for the procedure's clinical acceptance. 3. Request Level 2 review if Level 1 fails, then proceed to external review. 4. At external review, the IRO applies objective clinical standards — not Humana's internal policy — to determine whether the procedure is accepted medical practice. Plans frequently lose experimental denials at external review when major specialty societies endorse the treatment.

## Documentation to Gather

• Diagnosis confirmation: Endoscopy and biopsy pathology reports establishing the Barrett's esophagus diagnosis and dysplasia grade.
• Prior-treatment history: Records of any prior acid suppression therapy, surveillance endoscopies, and any prior ablation attempts.
• Clinical severity: Current clinical notes and pathology showing disease severity and the risk posed by non-treatment.
• Prescriber medical-necessity letter: A letter from a gastroenterologist or esophageal specialist citing current professional society position statements and clinical practice guidelines that support the requested ablation technique as accepted standard of care.

## Criteria-Mapping Strategy

Obtain Humana's medical policy and identify the specific criteria it uses to classify a procedure as experimental versus proven. Then show — using published guidelines from organizations such as the American Society for Gastrointestinal Endoscopy or the American College of Gastroenterology — that the requested technique meets the clinical-acceptance standard. Do not rely on specific study statistics; instead, show that the professional society guidelines affirmatively recommend or endorse the procedure for your diagnosis. A well-documented showing that the plan's own evidence criteria are satisfied by current guideline consensus is the most effective basis for reversal.